Human Molecular Genetics, 2000, Vol. 9, No. 9 1273-1281
© 2000 Oxford University Press
A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases
1Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel, 2 The IVF Unit, Department of Obstetrics and Gynecology, Barzilai Medical Center, Ben-Gurion University of the Negev, Ashkelon 78306, Israel, 3Department of Obstetrics and Gynecology, Sourasky Medical Center, The Sackler School of Medicine, Tel Aviv University, Tel Aviv 64239, Israel and 4The Research Laboratory, Herzog Hospital, PO Box 35300, Jerusalem 81351, Israel
Hypersensitivity to acetylcholinesterase inhibitors (anti-AChEs) causes severe nervous system symptoms under low dose exposure. In search of direct genetic origin(s) for this sensitivity, we studied six regions in the extended 22 kb promoter of the ACHE gene in individuals who presented adverse responses to anti-AChEs and in randomly chosen controls. Two contiguous mutations, a T
A substitution, disrupting a putative glucocorticoid response element, and a 4-bp deletion, abolishing one of two adjacent HNF3 binding sites, were identified 17 kb upstream of the transcription start site. Allele frequencies for these mutations were 0.006 and 0.012, respectively, in 333 individuals of various ethnic origins, with a strong linkage between the deletion and the biochemically neutral H322N mutation in the coding region of ACHE. Heterozygous carriers of the deletion included a proband who presented with acute hypersensitivity to the anti-AChE pyridostigmine and another with unexplained excessive vomiting during a fourth pregnancy following three spontaneous abortions. Electromobility shift assays, transfection studies and measurements of AChE levels in immortalized lymphocytes as well as in peripheral blood from both carriers and non-carriers, revealed functional relevance for this mutation both in vitro and in vivo and showed it to increase AChE expression, probably by alleviating competition between the two hepatocyte nuclear factor 3 binding sites. Moreover, AChE-overexpressing transgenic mice, unlike normal FVB/N mice, displayed anti-AChE hypersensitivity and failed to transcriptionally induce AChE production following exposure to anti-AChEs. Our findings point to promoter polymorphism(s) in the ACHE gene as the dominant susceptibility factor(s) for adverse responses to exposure or to treatment with anti-AChEs.
+ To whom correspondence should be addressed. Tel: +972 2 6585109; Fax: +972 2 6520258; Email: soreq@shum.huji.ac.il
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. C. R. Santos, I. Vala, C. Miguel, J. T. Barata, P. Garcao, P. Agostinho, M. Mendes, A. V. Coelho, A. Calado, C. R. Oliveira, et al. Expression and Subcellular Localization of a Novel Nuclear Acetylcholinesterase Protein J. Biol. Chem., August 31, 2007; 282(35): 25597 - 25603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. O. Browne, L. B. Moyal-Segal, D. Zumsteg, Y. David, O. Kofman, A. Berger, H. Soreq, and A. Friedman Coding region paraoxonase polymorphisms dictate accentuated neuronal reactions in chronic, sub-threshold pesticide exposure FASEB J, August 1, 2006; 20(10): 1733 - 1735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Meshorer, D. Toiber, D. Zurel, I. Sahly, A. Dori, E. Cagnano, L. Schreiber, D. Grisaru, F. Tronche, and H. Soreq Combinatorial Complexity of 5' Alternative Acetylcholinesterase Transcripts and Protein Products J. Biol. Chem., July 9, 2004; 279(28): 29740 - 29751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Sklan, A. Lowenthal, M. Korner, Y. Ritov, D. M. Landers, T. Rankinen, C. Bouchard, A. S. Leon, T. Rice, D. C. Rao, et al. Acetylcholinesterase/paraoxonase genotype and expression predict anxiety scores in Health, Risk Factors, Exercise Training, and Genetics study PNAS, April 13, 2004; 101(15): 5512 - 5517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. BRENNER, Y. HAMRA-AMITAY, T. EVRON, N. BONEVA, S. SEIDMAN, and H. SOREQ The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis FASEB J, February 1, 2003; 17(2): 214 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Darreh-Shori, O. Almkvist, Z. Z. Guan, A. Garlind, B. Strandberg, A.-L. Svensson, H. Soreq, E. Hellstrom-Lindahl, and A. Nordberg Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months Neurology, August 27, 2002; 59(4): 563 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Meshorer, C. Erb, R. Gazit, L. Pavlovsky, D. Kaufer, A. Friedman, D. Glick, N. Ben-Arie, and H. Soreq Alternative Splicing and Neuritic mRNA Translocation Under Long-Term Neuronal Hypersensitivity Science, January 18, 2002; 295(5554): 508 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Wilson, C. Riemer, D. W. Martindale, P. Schnupf, A. P. Boright, T. L. Cheung, D. M. Hardy, S. Schwartz, S. W. Scherer, L.-C. Tsui, et al. Comparative analysis of the gene-dense ACHE/TFR2 region on human chromosome 7q22 with the orthologous region on mouse chromosome 5 Nucleic Acids Res., March 15, 2001; 29(6): 1352 - 1365. [Abstract] [Full Text] [PDF]
|
|